Brief: Allarity Therapeutics' Stenoparib Sees Early Conclusion Of Phase 2 Trial In Advanced Ovarian Cancer
02/05/2024 13:12
May 2 (Reuters) - Allarity Therapeutics Inc ALLR.O :
* ALLARITY THERAPEUTICS’ STENOPARIB SHOWS CLEAR CLINICAL
BENEFIT
AND ACHIEVES SIGNIFICANT MILESTONE WITH EARLY CONCLUSION OF
PHASE 2 TRIAL IN ADVANCED OVARIAN CANCER
Source text for Eikon: ID:nGNXKwpQL
Further company coverage: ALLR.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Allarity Therapeutics
See all newsBrief: Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement
Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Allarity Therapeutics Q2 loss narrows as expenses fall
Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic